SCHEMBL1268839

SCHEMBL1268839

Cc1nc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ncc1Sc1ccc(S(=O)(=O)N2CCOCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.42
▸ KMT2A Q03164 6/20 0.42
▸ LMNA P02545 4/20 0.41
▸ MAPT P10636 4/20 0.41
▸ GAA P10253 2/20 0.41
▸ ALDH1A1 P00352 5/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ SLC40A1 Q9NP59 1/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.40
▸ EDNRA P25101 1/20 0.39
▸ ALOX5 P09917 1/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ MTOR P42345 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ BRCA1 P38398 1/20 0.39
▸ CCNT1 O60563 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269394 0.91 ALDH1A1 (0.42) MEN1KMT2ALMNAMAPTGAA
SCHEMBL1269704 0.90 GAA (0.46) KMT2ALMNAMAPTGAAALDH1A1
SCHEMBL1269715 0.86 MEN1 (0.43) MEN1KMT2ALMNAMAPTGAA
SCHEMBL1268782 0.85 MAPK1 (0.43) MEN1KMT2ALMNAMAPTGAA
SCHEMBL12931665 0.84 LMNA (0.45) KMT2ALMNAMAPTGAAALDH1A1
SCHEMBL1268653 0.83 SMN1; SMN2 (0.45) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL1269541 0.82 ALDH1A1 (0.42) MEN1KMT2ALMNAMAPTGAA
SCHEMBL1269670 0.81 KMT2A (0.42) MEN1KMT2ALMNAMAPTGAA
SCHEMBL1269828 0.81 ALDH1A1 (0.45) MEN1KMT2ALMNAMAPTALDH1A1
SCHEMBL1269543 0.81 ALDH1A1 (0.41) MEN1KMT2ALMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
EP-1786782-A2 BISARYL-SULFONAMIDES Amgen Inc. (US) 2007-05-23 — — EP disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed
WO-2006020830-A2 BISARYL-SULFONAMIDES AMGEN INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG MEN1 4841/4885KMT2A 1448/4885LMNA 2576/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG MEN1 4841/4885KMT2A 1448/4885LMNA 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback